30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Anika Therapeutics Announces Top-Line Results from CINGAL Trial in Knee OA -

In the Phase III 16-02 clinical trial of Anika Therapeutics' CINGAL, statistically significant results in pain reduction were not demonstrated at the primary endpoint of 26 weeks. Researchers observed significant improvements in pain, function and quality of life at levels consistent with or greater than results of the placebo-controlled study, as well as a strong safety profile. Patient follow-up in a prospectively designed extension phase will gather data through 39 weeks. (Anika Therapeutics, Inc., 6/20/18)